摘要
目的基于生物信息学分析尤文肉瘤的基因差异表达及功能预测,为尤文肉瘤的治疗提供帮助。方法通过GEO数据库寻找RNA数据集,通过limma包寻找差异基因并寻求可视化,对其进行信号通路分析和GO富集分析,最后进行基因互作网络的分析。结果在尤文肉瘤组织中共筛选出312个基因具有差异,其中192个上调基因,120个下调基因。通过细胞组成的研究,细胞外区域组分、细胞外区域、细胞外小泡、细胞外细胞器、细胞外泌体对尤文肉瘤影响较大。通过对生物进程的分析,细胞分化、系统发育、解剖结构、细胞发育、细胞发育过程影响较大。通过对分子功能的研究,蛋白结合、细胞黏附结合、蛋白质二聚体结合、胰岛素II受体结合、细胞外基质结合影响较大。通过基因互作网络发现,ANXA2和S100A10,ANXA2和S100A4,GRP和CCK,LAMA5和ITGA3,SCNN1A和SG1C1互作关系较为密切。结论ANXA2和S100A10,ANXA2和S100A4,GRP和CCK,LAMA5和ITGA3,SCNN1A和SG1C1互作关系较为密切,这些相互作用的基因编码蛋白可能调控尤文肉瘤的产生。
Objective To analyze the differential expression and functional prediction of genes in Ewing's sarcoma based on bioinformatics,providing help for the treatment of Ewing sarcoma.Methods The RNA data set was searched through GEO database,the differential genes were searched by limma package and visualized,the signal pathway analysis and GO enrichment analysis were performed,and the gene interaction network was finally analyzed.Results A total of 312 mRNA samples were selected from Ewing's sarcoma,among which 192 were up-regulated and 120 were down-regulated.Through the study of cell composition,the components of extracellular regions,extracellular regions,extracellular vesicles,extracellular organelles and exosomes had great influence on Ewing’s sarcoma.Through the analysis of biological processes,cell differentiation,phylogeny,anatomical structure,cell development,cell development process had a greater impact.Through the study of molecular functions,protein binding,cell adhesion binding,protein dimer binding,insulin II receptor binding and extracellular matrix binding had great influence.Through the gene interaction network,we found that ANXA2 and S100A10,ANXA2 and S100A4,GRP and CCK,LAMA5 and ITGA3,SCNN1A and SG1C1 closely interacted.Conclusion ANXA2 and S100A10,ANXA2 and S100A4,GRP and CCK,LAMA5 and ITGA3,SCNN1A and SG1C1 closely interact,and these interacting gene-coding proteins may be responsible for Ewing's sarcoma.
作者
韩广弢
李皓桓
HAN Guang-tao;LI Hao-huan(Department of Orthopedics,People's Hospital of Wuhan University,Hubei 430060,China)
出处
《中国医药生物技术》
2021年第1期27-31,共5页
Chinese Medicinal Biotechnology
基金
国家自然科学基金(81171760)。